Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Prostate Cancer

Free Subscription Articles published in J Urol Retrieve available abstracts of 206 articles: HTML format

Single Articles

April 2023
1. 
   Preoperative Circulating 11-Oxygenated Androgens Are Associated With Metastasis-free Survival in Localized Prostate Cancer.
   J Urol. 2023;209:815.
   PubMed    
   
   
   March 2023
2. JIN S, Wu L, Mai Z, Yan W, et al
   A Multicenter, Randomized, Single-Blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-Intermediate Risk Prostate Cancer. Letter.
   J Urol. 2023 Mar 16:101097JU0000000000003404. doi: 10.1097/JU.0000000000003404.
   PubMed    
   
   
   
3. HUSSAIN M, Sternberg CN, Efstathiou E, Fizazi K, et al
   Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial.
   J Urol. 2023;209:532-539.
   PubMed     Abstract available
   
   
   February 2023
4. SWAMI U, Hong A, El-Chaar NN, Ramaswamy K, et al
   The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients with Metastatic Castration-Sensitive Prostate Cancer.
   J Urol. 2023 Feb 15:101097JU0000000000003370. doi: 10.1097/JU.0000000000003370.
   PubMed     Abstract available
   
   
   
5. LEAPMAN MS, Wang R, Loeb S, Seibert TM, et al
   Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation.
   J Urol. 2023 Feb 8:101097JU0000000000003159. doi: 10.1097/JU.0000000000003159.
   PubMed     Abstract available
   
   
   
6. PATEL N, Hughes A, Zhang H, Brisbane W, et al
   Utility of MRI for Localizing Prostate Cancer near the Urethra in Men Who are Candidates for Focal Gland Ablation.
   J Urol. 2023 Feb 8:101097JU0000000000003197. doi: 10.1097/JU.0000000000003197.
   PubMed     Abstract available
   
   
   
7. 
   Patient-reported Outcomes After External Beam Radiotherapy With Low Dose Rate Brachytherapy Boost vs Radical Prostatectomy for Localized Prostate Cancer: Five-year Results From a Prospective Comparative Effectiveness Study.
   J Urol. 2023;209:450.
   PubMed    
   
   
   
8. SCHWEIZER MT, True L, Gulati R, Zhao Y, et al
   Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical Trial.
   J Urol. 2023;209:354-363.
   PubMed     Abstract available
   
   
   January 2023
9. TANEJA SS
   Urological Oncology: Prostate Cancer.
   J Urol. 2023 Jan 25:101097JU0000000000003180. doi: 10.1097/JU.0000000000003180.
   PubMed    
   
   
   
10. TOUIJER K, Plata Bello A
    Prevalence of High-Risk Prostate Cancer Metastasis to Cloquet's Ilioinguinal Lymph Node. Reply.
    J Urol. 2023 Jan 19:101097JU0000000000003178. doi: 10.1097/JU.0000000000003178.
    PubMed    
    
    
    
11. DE BARROS HA, Berrens AC, Donswijk ML, Wit EMK, et al
    Prevalence of High-Risk Prostate Cancer Metastasis to Cloquet's Ilioinguinal Lymph Node. Letter.
    J Urol. 2023 Jan 17:101097JU0000000000003177. doi: 10.1097/JU.0000000000003177.
    PubMed    
    
    
    
12. SAFARINEJAD MR, Safarinejad S, Shafiei N, Safarinejad S, et al
    Expression of Concern: G Protein beta3 Subunit Gene C825T Polymorphism and its Association with the Presence and Clinicopathological Characteristics of Prostate Cancer.
    J Urol. 2023 Jan 10:101097JU0000000000003145. doi: 10.1097/JU.0000000000003145.
    PubMed    
    
    
    
13. CARROLL P
    Gleason Grade 1 Prostate Cancer Volume at Biopsy Is Associated With Upgrading, but Not Adverse Pathology or Recurrence After Radical Prostatectomy: Results From a Large Institutional Cohort. Reply.
    J Urol. 2023;209:73.
    PubMed    
    
    
    
14. SHOJI S, Kaya T, Tanaka Y, Uemura K, et al
    Usefulness of LacdiNAc-glycosylated Prostate-specific Antigen Density for Predicting Pathological Findings of Magnetic Resonance Imaging-transrectal Ultrasound Fusion Image-guided Prostate Biopsy for the Patients With Highest Prostate Imaging Reportin
    J Urol. 2023;209:187-197.
    PubMed     Abstract available
    
    
    December 2022
15. LIN DW
    Point-Counterpoint: Active Surveillance Should Still be Preferred Management for All (or Nearly All) Men with Low Risk Prostate Cancer.
    J Urol. 2022 Dec 27:101097JU0000000000003134. doi: 10.1097/JU.0000000000003134.
    PubMed    
    
    
    
16. TIMILSHINA N, Alibhai SMH, Tomlinson G, Sander B, et al
    Long-Term Outcomes following Active Surveillance of Low-Grade Prostate Cancer: A Population-Based Study Using a Landmark Approach.
    J Urol. 2022 Dec 7:101097JU0000000000003097. doi: 10.1097/JU.0000000000003097.
    PubMed     Abstract available
    
    
    
17. HIGANO CS, Hafron J
    Adherence With Oral Anticancer Therapies: Clinical Trial versus Real-World Experiences with a Focus on Prostate Cancer.
    J Urol. 2022 Dec 6:101097JU0000000000003081. doi: 10.1097/JU.0000000000003081.
    PubMed     Abstract available
    
    
    
18. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022;208:1349-1351.
    PubMed    
    
    
    
19. ANDREWS JR, Ahmed ME, Sharma V, Britton C, et al
    Metastasis-directed Therapy Without Androgen Deprivation Therapy in Solitary Oligorecurrent Prostate Cancer.
    J Urol. 2022;208:1240-1249.
    PubMed     Abstract available
    
    
    
20. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Dec 1:101097JU0000000000003088. doi: 10.1097/JU.0000000000003088.
    PubMed    
    
    
    
21. ZHANG Y, Stopsack KH, Wu K, Song M, et al
    Post-diagnostic Zinc Supplement Use and Prostate Cancer Survival Among Men With Nonmetastatic Prostate Cancer.
    J Urol. 2022 Dec 1:101097JU0000000000003080. doi: 10.1097/JU.0000000000003080.
    PubMed     Abstract available
    
    
    November 2022
22. DE LA ROSETTE J, Dominguez-Escrig J, Zhang K, Teoh J, et al
    A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer.
    J Urol. 2022 Nov 28:101097JU0000000000003051. doi: 10.1097/JU.0000000000003051.
    PubMed     Abstract available
    
    
    
23. PITTMAN A, Moses KA, Washington SL 3rd
    Urologists in Advocacy: The Key to Addressing Disparities in Prostate Cancer.
    J Urol. 2022 Nov 17:101097JU0000000000003000. doi: 10.1097/JU.0000000000003000.
    PubMed    
    
    
    
24. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Nov 16:101097JU0000000000003046. doi: 10.1097/JU.0000000000003046.
    PubMed    
    
    
    
25. DAHMANI C, Caron P, Simonyan D, Lacombe L, et al
    Preoperative Circulating 11-Oxygenated Androgens Are Associated With Metastasis-free Survival in Localized Prostate Cancer.
    J Urol. 2022 Nov 14:101097JU0000000000003049. doi: 10.1097/JU.0000000000003049.
    PubMed     Abstract available
    
    
    
26. MARTINI A, Valerio M
    An Algorithm to Personalize Nerve Sparing in Men With Unilateral High-risk Prostate Cancer. Reply.
    J Urol. 2022 Nov 11:101097JU0000000000003055. doi: 10.1097/JU.0000000000003055.
    PubMed    
    
    
    
27. BOWER PE
    An Algorithm to Personalize Nerve Sparing in Men With Unilateral High-risk Prostate Cancer. Letter.
    J Urol. 2022 Nov 11:101097JU0000000000003054. doi: 10.1097/JU.0000000000003054.
    PubMed    
    
    
    
28. LANNES F, Baboudjian M, Ruffion A, Rouy M, et al
    Radioisotope-Guided Lymphadenectomy for Pelvic Lymph Node Staging in Patients with Intermediate- and High-risk Prostate Cancer (The Prospective SENTINELLE Study).
    J Urol. 2022 Nov 4:101097JU0000000000003043. doi: 10.1097/JU.0000000000003043.
    PubMed     Abstract available
    
    
    
29. OZMAN O, Tillier CN, van Muilekom E, van de Poll-Franse LV, et al
    Financial Toxicity After Robot-Assisted Radical Prostatectomy and Its Relation with Oncologic, Functional Outcomes.
    J Urol. 2022;208:978-986.
    PubMed     Abstract available
    
    
    
30. DOAN P, Scheltema MJ, Amin A, Shnier R, et al
    Final Analysis of the Magnetic Resonance Imaging in Active Surveillance Trial.
    J Urol. 2022;208:1028-1036.
    PubMed     Abstract available
    
    
    
31. MAZZONE E, Gandaglia G, Stabile A, Bravi CA, et al
    Not All Adverse Pathology Features Are Equal: Identifying Optimal Candidates for Adjuvant Radiotherapy Among Patients With Adverse Pathology at Radical Prostatectomy.
    J Urol. 2022;208:1046-1055.
    PubMed     Abstract available
    
    
    
32. FILSON CP, Zhu K, Huang Y, Zheng Y, et al
    Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance.
    J Urol. 2022;208:1037-1045.
    PubMed     Abstract available
    
    
    October 2022
33. PAUDEL R, Madan R, Qi J, Ferrante S, et al
    The Use and Short-term Outcomes of Men With National Comprehensive Cancer Network Favorable Intermediate-risk Prostate Cancer Managed With Active Surveillance: The Initial Michigan Urological Surgery Improvement Collaborative Experience.
    J Urol. 2022 Oct 13:101097JU0000000000003012. doi: 10.1097/JU.0000000000003012.
    PubMed     Abstract available
    
    
    
34. HANSEN NF, Linscott JA, Hayn MH, Ryan ST, et al
    PSA testing behaviors for prostate cancer screening among U.S. immigrants: a cross-sectional analysis using the NHIS.
    J Urol. 2022 Oct 11:101097JU0000000000002993. doi: 10.1097/JU.0000000000002993.
    PubMed     Abstract available
    
    
    
35. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Oct 10:101097JU0000000000003008. doi: 10.1097/JU.0000000000003008.
    PubMed    
    
    
    
36. BABOUDJIAN M, Ploussard G
    Gleason Grade 1 Prostate Cancer Volume at Biopsy is Associated with Upgrading, but Not Adverse Pathology or Recurrence after Radical Prostatectomy: Results from a Large Institutional Cohort. Letter.
    J Urol. 2022 Oct 10:101097JU0000000000002991. doi: 10.1097/JU.0000000000002991.
    PubMed    
    
    
    
37. ZATTONI F, Marra G, Kasivisvanathan V, Grummet J, et al
    The Detection of Prostate Cancer with Magnetic Resonance Imaging-Targeted Prostate Biopsies is Superior with the Transperineal vs the Transrectal Approach. A European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi
    J Urol. 2022;208:830-837.
    PubMed     Abstract available
    
    
    
38. RAVI P, Kwak L, Xie W, Kelleher K, et al
    Neoadjuvant Novel Hormonal Therapy Followed by Prostatectomy versus Up-Front Prostatectomy for High-Risk Prostate Cancer: A Comparative Analysis.
    J Urol. 2022;208:838-845.
    PubMed     Abstract available
    
    
    
39. OAKE JD, Shiff B, Harasemiw O, Tangri N, et al
    The Comparative Outcomes of Radical Prostatectomy versus Radiotherapy for Nonmetastatic Prostate Cancer: A Longitudinal, Population-Based Analysis.
    J Urol. 2022;208:846-854.
    PubMed     Abstract available
    
    
    September 2022
40. LABBATE CV, Klotz L, Morrow M, Cooperberg M, et al
    Focal Therapy for Prostate Cancer -Evolutionary Parallels to Breast Cancer Treatment.
    J Urol. 2022 Sep 21:101097JU0000000000002972. doi: 10.1097/JU.0000000000002972.
    PubMed     Abstract available
    
    
    
41. ROULEAU M, Neveu B, Caron P, Morin F, et al
    Extensive Alteration of Androgen Precursor Levels after Castration in Prostate Cancer Patients and Their Association with Active Androgen Level.
    J Urol. 2022 Sep 14:101097JU0000000000002923. doi: 10.1097/JU.0000000000002923.
    PubMed     Abstract available
    
    
    
42. JOYCE DD, Sharma V, Jiang DH, Van Houten HK, et al
    Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients.
    J Urol. 2022 Sep 12:101097JU0000000000002856. doi: 10.1097/JU.0000000000002856.
    PubMed     Abstract available
    
    
    
43. LOPEZ BM, Boville GA, Bernardos GB, Marckert XA, et al
    Focal Therapy of Prostate Cancer Index Lesion with Irreversible Electroporation. A Prospective Study with a Median Follow-Up of Three Years.
    J Urol. 2022 Sep 8:101097JU0000000000002970. doi: 10.1097/JU.0000000000002970.
    PubMed     Abstract available
    
    
    
44. DE LA CALLE CM, Mamawala MM, Landis P, Macura KJ, et al
    Clinical Significance of Perineural Invasion in Men with Grade Group 1 Prostate Cancer on Active Surveillance.
    J Urol. 2022 Sep 8:101097JU0000000000002963. doi: 10.1097/JU.0000000000002963.
    PubMed     Abstract available
    
    
    
45. SHEE K, Washington SL 3rd, Cowan JE, de la Calle CM, et al
    Gleason Grade 1 Prostate Cancer Volume at Biopsy is Associated with Upgrading, but Not Adverse Pathology or Recurrence after Radical Prostatectomy: Results from a Large Institutional Cohort.
    J Urol. 2022 Sep 6:101097JU0000000000002956. doi: 10.1097/JU.0000000000002956.
    PubMed     Abstract available
    
    
    
46. SHIRK JD, Reiter R, Wallen EM, Pak R, et al
    Effect of 3-Dimensional, Virtual Reality Models for Surgical Planning of Robotic Prostatectomy on Trifecta Outcomes: A Randomized Clinical Trial.
    J Urol. 2022;208:618-625.
    PubMed     Abstract available
    
    
    August 2022
47. DE B, Pasalic D, Barocas DA, Wallis CJD, et al
    Patient-Reported Outcomes after External Beam Radiotherapy with Low Dose-Rate Brachytherapy Boost versus Radical Prostatectomy for Localized Prostate Cancer: Five-Year Results from a Prospective Comparative Effectiveness Study.
    J Urol. 2022 Aug 25:101097JU0000000000002902. doi: 10.1097/JU.0000000000002902.
    PubMed     Abstract available
    
    
    
48. TROCK BJ, Jing Y, Mabey B, Sangale Z, et al
    Cell Cycle Progression Score, But Not PTEN Loss, Is an Independent Prognostic Factor for Metastasis in Intermediate- and High-Risk Prostate Cancer in Men Treated with and without Salvage Radiotherapy.
    J Urol. 2022 Aug 25:101097JU0000000000002922. doi: 10.1097/JU.0000000000002922.
    PubMed    
    
    
    
49. KIM IE JR, Pareek G
    The Key to Addressing Disparities in Prostate Cancer: Urologists in Advocacy?
    J Urol. 2022 Aug 24:101097JU0000000000002930. doi: 10.1097/JU.0000000000002930.
    PubMed    
    
    
    
50. RACHUBINSKI P, Witt JH, Budaus L, Zinke J, et al
    Precision-Guidance vs. Systematic Sampling: Optimizing Biopsy Assessment of Secondary Prostate Cancer Suspicious mpMRI Lesions.
    J Urol. 2022 Aug 24:101097JU0000000000002921. doi: 10.1097/JU.0000000000002921.
    PubMed     Abstract available
    
    
    
51. GABRIELSON AT, Choi U, Fletcher SA, Pavlovich CP, et al
    Lost in Transparency: The 21st Century Cures Act ("Open Notes") and Prostate Cancer Care.
    J Urol. 2022 Aug 19:101097JU0000000000002924. doi: 10.1097/JU.0000000000002924.
    PubMed    
    
    
    
52. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Aug 19:101097JU0000000000002909. doi: 10.1097/JU.0000000000002909.
    PubMed    
    
    
    
53. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Aug 16:101097JU0000000000002870. doi: 10.1097/JU.0000000000002870.
    PubMed    
    
    
    
54. ABUSAMRA SM, Solorzano MA, Luke M, Quarles J, et al
    Satisfaction with Clinician-Led Germline Genetic Counseling in Patients with Prostate Cancer.
    J Urol. 2022 Aug 5:101097JU0000000000002865. doi: 10.1097/JU.0000000000002865.
    PubMed     Abstract available
    
    
    
55. GLOGER S, Ubrig B, Boy A, Leyh-Bannurah SR, et al
    Bilateral Peritoneal Flaps Reduce Incidence and Complications of Lymphoceles after Robotic Radical Prostatectomy with Pelvic Lymph Node Dissection-Results of the Prospective Randomized Multicenter Trial ProLy.
    J Urol. 2022;208:333-340.
    PubMed     Abstract available
    
    
    
56. GOODE PS, Johnson TM 2nd, Newman DK, Vaughan CP, et al
    Perioperative Mobile Telehealth Program for Post-Prostatectomy Incontinence: A Randomized Clinical Trial.
    J Urol. 2022;208:379-387.
    PubMed     Abstract available
    
    
    
57. ABOU ZEINAB M, Beksac AT, Corse T, Talamini S, et al
    The Multi-Institutional Experience in Single-Port Robotic Transvesical Simple Prostatectomy for Benign Prostatic Hyperplasia Management.
    J Urol. 2022;208:369-378.
    PubMed     Abstract available
    
    
    July 2022
58. BRANT A, Lewicki P, Wu X, Sze C, et al
    Impact of Left-digit Age Bias in the Treatment of Localized Prostate Cancer.
    J Urol. 2022 Jul 28:101097JU0000000000002857. doi: 10.1097/JU.0000000000002857.
    PubMed     Abstract available
    
    
    
59. EASTHAM JA, Boorjian SA, Kirkby E
    Clinically Localized Prostate Cancer: AUA/ASTRO Guideline.
    J Urol. 2022 Jul 5:101097JU0000000000002854. doi: 10.1097/JU.0000000000002854.
    PubMed    
    
    
    
60. WESTHOFEN T, Buchner A, Kasivisvanathan V, Lennartz S, et al
    The Added Value of Baseline Health-Related Quality of Life in Predicting Survival in High-Risk Prostate Cancer Patients Following Radical Prostatectomy.
    J Urol. 2022 Jul 5:101097JU0000000000002826. doi: 10.1097/JU.0000000000002826.
    PubMed     Abstract available
    
    
    
61. FAN S, Zhang Z, Wang J, Xiong S, et al
    Robot-Assisted Radical Prostatectomy Using the KangDuo Surgical Robot-01 System: A Prospective, Single-Center, Single-Arm Clinical Study.
    J Urol. 2022;208:119-127.
    PubMed     Abstract available
    
    
    
62. TOPS SCM, Grootenhuis JGA, Derksen AM, Giardina F, et al
    The Effect of Different Types of Prostate Biopsy Techniques on Post-Biopsy Infectious Complications.
    J Urol. 2022;208:109-118.
    PubMed     Abstract available
    
    
    June 2022
63. STINESEN KOLLBERG K, Holmberg E, Josefsson A, Hugosson J, et al
    Prostate-specific antigen (PSA) and biopsy contamination in the Goteborg-1 randomized, population-based, prostate cancer screening trial.
    J Urol. 2022 Jun 30:101097JU0000000000002835. doi: 10.1097/JU.0000000000002835.
    PubMed     Abstract available
    
    
    
64. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Jun 27:101097JU0000000000002796. doi: 10.1097/JU.0000000000002796.
    PubMed    
    
    
    
65. XUE X, Yang X, Ji Z, Xie Y, et al
    Representation in Online Prostate Cancer Content Lacks Racial and Ethnic Diversity: Implications for Black and Latinx Men. Letter.
    J Urol. 2022 Jun 21:101097JU0000000000002830. doi: 10.1097/JU.0000000000002830.
    PubMed    
    
    
    
66. ABOU ZEINAB M, Kaouk J
    The Multi-Institutional Experience in Single-Port Robotic Transvesical Simple Prostatectomy for Benign Prostatic Hyperplasia Management. Reply.
    J Urol. 2022 Jun 3:101097JU0000000000002785. doi: 10.1097/JU.0000000000002785.
    PubMed    
    
    
    
67. TIAN Y, Zhang H, Luo G
    The Multi-Institutional Experience in Single-Port Robotic Transvesical Simple Prostatectomy for Benign Prostatic Hyperplasia Management. Letter.
    J Urol. 2022 Jun 3:101097JU0000000000002784. doi: 10.1097/JU.0000000000002784.
    PubMed    
    
    
    
68. TURCHAN WT, Cutright D, Wu T, Leng JX, et al
    Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup.
    J Urol. 2022;207:1236-1245.
    PubMed     Abstract available
    
    
    May 2022
69. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 May 20:101097JU0000000000002745. doi: 10.1097/JU.0000000000002745.
    PubMed    
    
    
    
70. STEPHENSON AJ, Vourganti S
    Pro: MRI-Targeting Leads to Overtreatment of Prostate Cancer.
    J Urol. 2022 May 12:101097JU0000000000002776. doi: 10.1097/JU.0000000000002776.
    PubMed    
    
    
    
71. SIDDIQUI MM
    Con: MRI-Targeting Leads to Overtreatment of Prostate Cancer.
    J Urol. 2022 May 12:101097JU0000000000002777. doi: 10.1097/JU.0000000000002777.
    PubMed    
    
    
    
72. COLE AP, Chen X, Langbein BJ, Giganti F, et al
    Geographic Variability, Time Trends and Association of Preoperative MRI with Surgical Outcomes for Elderly US Men with Prostate Cancer: A SEER-Medicare Analysis.
    J Urol. 2022 May 10:101097JU0000000000002736. doi: 10.1097/JU.0000000000002736.
    PubMed     Abstract available
    
    
    
73. EASTHAM JA, Auffenberg GB, Barocas DA, Chou R, et al
    Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery and Follow-up.
    J Urol. 2022 May 10:101097JU0000000000002758. doi: 10.1097/JU.0000000000002758.
    PubMed     Abstract available
    
    
    
74. EASTHAM JA, Auffenberg GB, Barocas DA, Chou R, et al
    Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging and Risk-Based Management.
    J Urol. 2022 May 10:101097JU0000000000002757. doi: 10.1097/JU.0000000000002757.
    PubMed     Abstract available
    
    
    
75. EASTHAM JA, Auffenberg GB, Barocas DA, Chou R, et al
    Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Part III: Principles of Radiation and Future Directions.
    J Urol. 2022 May 10:101097JU0000000000002759. doi: 10.1097/JU.0000000000002759.
    PubMed     Abstract available
    
    
    
76. ZHANG Y, Song M, Mucci LA, Giovannucci EL, et al
    Regular, Long-Duration Multivitamin Use and Risk of Overall and Aggressive Prostate Cancer in the Health Professionals Follow-Up Study.
    J Urol. 2022 May 6:101097JU0000000000002735. doi: 10.1097/JU.0000000000002735.
    PubMed     Abstract available
    
    
    
77. RADHAKRISHNAN A, Wallner LP, Skolarus TA, George AK, et al
    Exploring Variation in the Receipt of Recommended Active Surveillance for Men with Favorable-Risk Prostate Cancer.
    J Urol. 2022 May 6:101097JU0000000000002734. doi: 10.1097/JU.0000000000002734.
    PubMed     Abstract available
    
    
    
78. 
    Findings in 1,123 Men with Preoperative (68)Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography and Multiparametric Magnetic Resonance Imaging Compared to Totally Embedded Radical Prostatectomy Histopathology: Im
    J Urol. 2022;207:1166.
    PubMed    
    
    
    
79. GONDOPUTRO W, Thompson J, Evans M, Bolton D, et al
    How Does Age Affect Urinary Continence following Robot-Assisted Radical Prostatectomy? A Prospective Multi-Institutional Study Using Independently Collected, Validated Questionnaires.
    J Urol. 2022;207:1048-1056.
    PubMed     Abstract available
    
    
    April 2022
80. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Apr 25:101097JU0000000000002705. doi: 10.1097/JU.0000000000002705.
    PubMed    
    
    
    
81. FRANLUND M, Mansson M, Godtman RA, Aus G, et al
    Results from 22 years of Follow-Up in the Goteborg Randomized Population-Based Prostate Cancer Screening Trial.
    J Urol. 2022 Apr 15:101097JU0000000000002696. doi: 10.1097/JU.0000000000002696.
    PubMed     Abstract available
    
    
    
82. LEWICKI P, Brant A, Shoag JE
    Re: A Nationwide Analysis of Risk of Prostate Cancer Diagnosis and Mortality following an Initial Negative TRUS-Biopsy with Long-Term Follow-Up.
    J Urol. 2022 Apr 8:101097JU0000000000002700. doi: 10.1097/JU.0000000000002700.
    PubMed    
    
    
    
83. NYAME YA, Schraidt JA, Chakoian M, Nissenberg MG, et al
    A Patient-Centered Approach to Research Prioritization in Prostate Cancer.
    J Urol. 2022 Apr 8:101097JU0000000000002694. doi: 10.1097/JU.0000000000002694.
    PubMed     Abstract available
    
    
    
84. JIBARA GA, Perera M, Vertosick EA, Sjoberg DD, et al
    Association of Family History of Cancer with Clinical and Pathological Outcomes for Prostate Cancer Patients on Active Surveillance.
    J Urol. 2022 Apr 4:101097JU0000000000002668. doi: 10.1097/JU.0000000000002668.
    PubMed     Abstract available
    
    
    
85. DASKIVICH TJ, Gale R, Luu M, Naser-Tavakolian A, et al
    Variation in Communication of Competing Risks of Mortality in Prostate Cancer Treatment Consultations.
    J Urol. 2022 Apr 4:101097JU0000000000002675. doi: 10.1097/JU.0000000000002675.
    PubMed     Abstract available
    
    
    
86. PERERA M, Assel MJ, Benfante NE, Vickers AJ, et al
    Oncologic Outcomes of Total Length Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer.
    J Urol. 2022 Apr 1:101097JU0000000000002685. doi: 10.1097/JU.0000000000002685.
    PubMed     Abstract available
    
    
    March 2022
87. MONTORSI F, Mazzone E, Gandaglia G, Stabile A, et al
    Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. Letter.
    J Urol. 2022 Mar 29:101097JU0000000000002680. doi: 10.1097/JU.0000000000002680.
    PubMed    
    
    
    
88. CHIERIGO F, Borghesi M, Mantica G, Terrone C, et al
    Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. Reply.
    J Urol. 2022 Mar 29:101097JU0000000000002681. doi: 10.1097/JU.0000000000002681.
    PubMed    
    
    
    
89. DURSUN F, Wang CP, MacCarthy D, Mansour AM, et al
    Absolute PSA after 6 Months of Androgen Deprivation Therapy is a Predictor of Overall and Cancer Specific Mortality in Men with Hormone-Sensitive Prostate Cancer.
    J Urol. 2022 Mar 28:101097JU0000000000002676. doi: 10.1097/JU.0000000000002676.
    PubMed     Abstract available
    
    
    
90. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Mar 17:101097JU0000000000002511. doi: 10.1097/JU.0000000000002511.
    PubMed    
    
    
    
91. BRIGHT JR, Lis RT, Ku AT, Terrigino NT, et al
    PROSTATE-SPECIFIC Membrane Antigen Is a Biomarker for Residual Disease Following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate Cancer.
    J Urol. 2022 Mar 1:101097JU0000000000002492. doi: 10.1097/JU.0000000000002492.
    PubMed     Abstract available
    
    
    
92. KAN KM, Tin AL, Stearns GL, Eastham JA, et al
    De Novo Urinary Storage Symptoms Are Common after Radical Prostatectomy: Incidence, Natural History and Predictors.
    J Urol. 2022;207:601-608.
    PubMed     Abstract available
    
    
    
93. BAHOUTH Z, Laniado M, Fowler R, Charlesworth PJS, et al
    Positive Surgical Margins Rate of Retzius-Sparing Robot-Assisted Radical Prostatectomy in a Contemporary, Unselected Cohort.
    J Urol. 2022;207:609-616.
    PubMed     Abstract available
    
    
    February 2022
94. KAWA SM, Stroomberg HV, Larsen SB, Helgstrand JT, et al
    A Nationwide Analysis of Risk of Prostate Cancer Diagnosis and Mortality following an Initial Negative TRUS-Biopsy with Long-Term Follow-Up.
    J Urol. 2022 Feb 25:101097JU0000000000002491. doi: 10.1097/JU.0000000000002491.
    PubMed     Abstract available
    
    
    
95. MAGNANI CJ, Hernandez-Boussard T, Baker LC, Goldhaber-Fiebert JD, et al
    Cost-Effectiveness Analysis and Microsimulation of Serial Multiparametric Magnetic Resonance Imaging in Active Surveillance of Localized Prostate Cancer.
    J Urol. 2022 Feb 25:101097JU0000000000002490. doi: 10.1097/JU.0000000000002490.
    PubMed     Abstract available
    
    
    
96. KANG DW, Fairey AS, Boule NG, Field CJ, et al
    A Randomized Trial of the Effects of Exercise on Anxiety, Fear of Cancer Progression and Quality of Life in Prostate Cancer Patients on Active Surveillance.
    J Urol. 2022 Feb 17:101097JU0000000000002334. doi: 10.1097/JU.0000000000002334.
    PubMed     Abstract available
    
    
    
97. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Feb 16:101097JU0000000000002477. doi: 10.1097/JU.0000000000002477.
    PubMed    
    
    
    
98. LOEB S, Borno HT, Gomez S, Ravenell J, et al
    Representation in Online Prostate Cancer Content Lacks Racial and Ethnic Diversity: Implications for Black and Latinx Men.
    J Urol. 2022 Feb 4:101097JU0000000000002257. doi: 10.1097/JU.0000000000002257.
    PubMed     Abstract available
    
    
    
99. KACHANOV M, Leyh-Bannurah SR, Roberts MJ, Sauer M, et al
    Optimizing Combined Magnetic Resonance Imaging (MRI)-Targeted and Systematic Biopsy Strategies: Sparing the Multiparametric MRI-Negative Transitional Zone in Presence of Exclusively Peripheral Multiparametric MRI-Suspect Lesions.
    J Urol. 2022;207:333-340.
    PubMed     Abstract available
    
    
    
100. OTLES E, Denton BT, Qu B, Murali A, et al
     Development and Validation of Models to Predict Pathological Outcomes of Radical Prostatectomy in Regional and National Cohorts.
     J Urol. 2022;207:358-366.
     PubMed     Abstract available
     
     
     
101. CLEMENTS MB, Tin AL, Estes CL, Jibara G, et al
     Characterization of Symptoms after Radical Prostatectomy and Their Relation to Postoperative Complications.
     J Urol. 2022;207:367-374.
     PubMed     Abstract available
     
     
     January 2022
102. ANDRUSKA N, Fischer-Valuck BW, Waters M, Diaz EJ, et al
     Survival Outcomes in Men with Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Treated with Prostate-only versus Whole Pelvic Radiation Therapy.
     J Urol. 2022 Jan 27:101097JU0000000000002455. doi: 10.1097/JU.0000000000002455.
     PubMed     Abstract available
     
     
     
103. KUPPERMANN D, Calais J, Marks LS
     Imaging Prostate Cancer: Clinical Utility of Prostate-specific Membrane Antigen (PSMA).
     J Urol. 2022 Jan 27:101097JU0000000000002457. doi: 10.1097/JU.0000000000002457.
     PubMed     Abstract available
     
     
     
104. SCHIFF H
     Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States. Letter.
     J Urol. 2022 Jan 26:101097JU0000000000002456. doi: 10.1097/JU.0000000000002456.
     PubMed    
     
     
     
105. ROSENBERG JE, Jarosek S, Spilseth B, Huang YH, et al
     Diagnosing Prostate Cancer: The Role of Intravesicular Prostatic Gland Protrusion on Accuracy of Prostate Biopsies.
     J Urol. 2022 Jan 26:101097JU0000000000002448. doi: 10.1097/JU.0000000000002448.
     PubMed     Abstract available
     
     
     
106. EGGENER S, Siemens DR
     Prostate Cancer, Decisional Regret and Exercise.
     J Urol. 2022 Jan 26:101097JU0000000000002453. doi: 10.1097/JU.0000000000002453.
     PubMed    
     
     
     
107. WANG M, Semerjian A, Lane BR, George AK, et al
     Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort. Letter.
     J Urol. 2022 Jan 20:101097JU0000000000002442. doi: 10.1097/JU.0000000000002442.
     PubMed    
     
     
     
108. PLATA BELLO A, Apatov SE, Benfante NE, Rivero Belenchon I, et al
     Prevalence of High-Risk Prostate Cancer Metastasis to Cloquet's Ilioinguinal Lymph Node.
     J Urol. 2022 Jan 20:101097JU0000000000002439. doi: 10.1097/JU.0000000000002439.
     PubMed     Abstract available
     
     
     
109. SHAHAIT M, Cheaib JG, Davicioni E, Liu Y, et al
     Does Perioperative Testosterone Predict Post-prostatectomy Genomic Risk Score?
     J Urol. 2022 Jan 20:101097JU0000000000002440. doi: 10.1097/JU.0000000000002440.
     PubMed     Abstract available
     
     
     
110. PAN A, Reingold RE, Zhao JL, Moy A, et al
     Dermatologic Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide.
     J Urol. 2022 Jan 12:101097JU0000000000002425. doi: 10.1097/JU.0000000000002425.
     PubMed     Abstract available
     
     
     
111. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2022 Jan 7:101097JU0000000000002413. doi: 10.1097/JU.0000000000002413.
     PubMed    
     
     
     
112. TANAKA T, Kawashima A, Rangel LJ, Schulte PJ, et al
     Long Term Risk of Clinical Progression Utilizing MRI Findings of Locally Recurrent Prostate Cancer in Patients with Biochemical Recurrence Following Radical Prostatectomy.
     J Urol. 2022 Jan 4:101097JU0000000000002421. doi: 10.1097/JU.0000000000002421.
     PubMed     Abstract available
     
     
     
113. NAYAK JG
     The Association Between Income Status and Treatment Selection for Prostate Cancer in a Universal Healthcare System: A Population-Based Analysis. Reply.
     J Urol. 2022 Jan 4:101097JU0000000000002419. doi: 10.1097/JU.0000000000002419.
     PubMed    
     
     
     
114. GROSSO AA, Di Maida F, Mari A, Minervini A, et al
     The Association Between Income Status and Treatment Selection for Prostate Cancer in a Universal Health Care System: A Population-Based Analysis. Letter.
     J Urol. 2022 Jan 4:101097JU0000000000002418. doi: 10.1097/JU.0000000000002418.
     PubMed    
     
     
     
115. CHAPPIDI MR, Bell A, Cowan JE, Greenberg SA, et al
     The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate Cancer.
     J Urol. 2022 Jan 4:101097JU0000000000002420. doi: 10.1097/JU.0000000000002420.
     PubMed     Abstract available
     
     
     
116. LUCKENBAUGH AN, Wallis CJD, Huang LC, Wittmann D, et al
     Association Between Treatment for Localized Prostate Cancer and Mental Health Outcomes.
     J Urol. 2022 Jan 3:101097JU0000000000002370. doi: 10.1097/JU.0000000000002370.
     PubMed     Abstract available
     
     
     
117. PINTHUS JH, Duivenvoorden WCM, Klotz L, Mukherjee SD, et al
     Low Serum Testosterone in Men With Newly Diagnosed Androgen-Deprivation Therapy-Naive Prostate Cancer and Its Relationship to Cardiovascular Risk Factors-A Radical PC Substudy.
     J Urol. 2022 Jan 3:101097JU0000000000002384. doi: 10.1097/JU.0000000000002384.
     PubMed     Abstract available
     
     
     
118. LEE A, Chen K, Tay KJ
     Can We Avoid a Systematic Biopsy in Men with PI-RADS((R)) 5? Letter.
     J Urol. 2022;207:240-241.
     PubMed    
     
     
     
119. TAFURI A, Iwata A, Shakir A, Iwata T, et al
     Can We Avoid a Systematic Biopsy in Men with PI-RADS(R) 5? Reply.
     J Urol. 2022;207:241-242.
     PubMed    
     
     
     
120. CORKUM MT, Loblaw DA, Morton G, Louie AV, et al
     Radiation Oncologist Consultations Prior to Radical Prostatectomy: Disparities and Opportunities.
     J Urol. 2022;207:118-126.
     PubMed     Abstract available
     
     
     
121. CHANG P, Wagner AA, Regan MM, Smith JA, et al
     Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium.
     J Urol. 2022;207:127-136.
     PubMed     Abstract available
     
     
     
122. WILLIAMS C, Ahdoot M, Daneshvar MA, Hague C, et al
     Why Does Magnetic Resonance Imaging-Targeted Biopsy Miss Clinically Significant Cancer?
     J Urol. 2022;207:95-107.
     PubMed     Abstract available
     
     
     
123. PATEL HD, Koehne EL, Shea SM, Fang AM, et al
     Systematic versus Targeted Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy among Men with Visible Lesions.
     J Urol. 2022;207:108-117.
     PubMed     Abstract available
     
     
     December 2021
124. WASHINGTON SL 3RD, Gore JL, Nyame YA
     Translating Patient-Centered Research into Educational Resources to Address Racial Inequities in Prostate Cancer.
     J Urol. 2021 Dec 30:101097JU0000000000002417. doi: 10.1097/JU.0000000000002417.
     PubMed    
     
     
     
125. ALKHATIB K, Labban M, Briggs L, Nguyen DD, et al
     Does Veteran Status Mitigate Racial Disparities in Prostate Cancer Screening? Analysis of Prostate-specific Antigen Screening Patterns in the 2018 Behavioral Risk Factor Surveillance System Data.
     J Urol. 2021 Dec 30:101097JU0000000000002379. doi: 10.1097/JU.0000000000002379.
     PubMed     Abstract available
     
     
     
126. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2021 Dec 17:101097JU0000000000002377. doi: 10.1097/JU.0000000000002377.
     PubMed    
     
     
     
127. KAN WC, Hsieh KL, Chen YC, Ho CH, et al
     Comparison of Surgical or Medical Castration-Related Cardiotoxicity in Patients With Prostate Cancer.
     J Urol. 2021 Dec 2:101097JU0000000000002340. doi: 10.1097/JU.0000000000002340.
     PubMed     Abstract available
     
     
     
128. LONERGAN PE, Washington SL 3rd, Cowan JE, Zhao S, et al
     Androgen Deprivation Therapy and the Risk of Dementia after Treatment for Prostate Cancer.
     J Urol. 2021 Dec 2:101097JU0000000000002335. doi: 10.1097/JU.0000000000002335.
     PubMed     Abstract available
     
     
     
129. KINNAIRD A, Yerram NK, O'Connor L, Brisbane W, et al
     MRI-guided Biopsy in Active Surveillance of Prostate Cancer.
     J Urol. 2021 Dec 2:101097JU0000000000002343. doi: 10.1097/JU.0000000000002343.
     PubMed     Abstract available
     
     
     
130. WAISMAN MALARET AJ, Chang P, Zhu K, Zheng Y, et al
     Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results From the Canary PASS Cohort.
     J Urol. 2021 Dec 2:101097JU0000000000002354. doi: 10.1097/JU.0000000000002354.
     PubMed     Abstract available
     
     
     
131. SHANKAR PR, Ellimoottil C, George AK, Hadj-Moussa M, et al
     Testing-Related Health Impact of Transrectal and Transperineal Prostate Biopsy as Assessed by Health Utilities.
     J Urol. 2021;206:1403-1410.
     PubMed     Abstract available
     
     
     November 2021
132. CHEN K, Murphy D, Lawrentschuk N
     Active Surveillance for Low-Risk Prostate Cancer: The Uphill Battles and the Unnecessary Ones.
     J Urol. 2021 Nov 17:101097JU0000000000002348. doi: 10.1097/JU.0000000000002348.
     PubMed    
     
     
     
133. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2021 Nov 17:101097JU0000000000002326. doi: 10.1097/JU.0000000000002326.
     PubMed    
     
     
     
134. COOPERBERG MR, Lin DW, Morgan TM, Chapin BF, et al
     Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer.
     J Urol. 2021 Nov 15:101097JU0000000000002341. doi: 10.1097/JU.0000000000002341.
     PubMed    
     
     
     
135. WESTHOFEN T, Buchner A, Schlenker B, Becker A, et al
     Timing of Radiotherapy after Radical Prostatectomy: Effects on Health-Related Quality of Life.
     J Urol. 2021;206:1192-1203.
     PubMed     Abstract available
     
     
     
136. KOWALCZYK KJ, Madi RH, Eden CG, Sooriakumaran P, et al
     Comparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series.
     J Urol. 2021;206:1184-1191.
     PubMed     Abstract available
     
     
     October 2021
137. LEE MC, Erickson TR, Stock S, Howard LE, et al
     Association Between Delay to Radical Prostatectomy and Clinically Meaningful Outcomes Among Patients with Intermediate- and High-Risk Localized Prostate Cancer.
     J Urol. 2021 Oct 25:101097JU0000000000002304. doi: 10.1097/JU.0000000000002304.
     PubMed     Abstract available
     
     
     
138. LOZANO-LORCA M, Olmedo-Requena R, Rodriguez-Barranco M, Redondo-Sanchez D, et al
     Salivary Melatonin Rhythm and Prostate Cancer: CAPLIFE Study.
     J Urol. 2021 Oct 25:101097JU0000000000002294. doi: 10.1097/JU.0000000000002294.
     PubMed     Abstract available
     
     
     
139. DASKIVICH TJ, Luu M, Freedland SJ, Sandler H, et al
     Development and Validation of an Improved Pathological Nodal Staging System in Men With Prostate Cancer.
     J Urol. 2021 Oct 25:101097JU0000000000002256. doi: 10.1097/JU.0000000000002256.
     PubMed     Abstract available
     
     
     
140. YU W, Guo J
     Survival after Radical Prostatectomy vs. Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. Letter.
     J Urol. 2021 Oct 25:101097JU0000000000002302. doi: 10.1097/JU.0000000000002302.
     PubMed    
     
     
     
141. RAVEENTHIRAN S, Yaxley WJ, Franklin T, Coughlin G, et al
     Findings in 1123 Men with Pre-operative (68)Ga-PSMA PET/CT and mpMRI Compared to Totally Embedded Radical Prostatectomy Histopathology. Implications for the Diagnosis and Management of Prostate Cancer.
     J Urol. 2021 Oct 25:101097JU0000000000002293. doi: 10.1097/JU.0000000000002293.
     PubMed     Abstract available
     
     
     
142. 
     Urological Oncology: Prostate Cancer.
     J Urol. 2021 Oct 18:101097JU0000000000002285. doi: 10.1097/JU.0000000000002285.
     PubMed    
     
     
     
143. KAPLAN-MARANS E
     Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS). Letter.J Urol; 206: 613.
     J Urol. 2021 Oct 11:101097JU0000000000002288. doi: 10.1097/JU.0000000000002288.
     PubMed    
     
     
     
144. ZHANG KW, Guha A
     Response to "Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS): Letter."
     J Urol. 2021 Oct 11:101097JU0000000000002289. doi: 10.1097/JU.0000000000002289.
     PubMed    
     
     
     
145. URKMEZ A, Demirel C, Altok M, Bathala TK, et al
     Freehand versus Grid-Based Transperineal Prostate Biopsy: A Comparison of Anatomical Region Yield and Complications.
     J Urol. 2021;206:894-902.
     PubMed     Abstract available
     
     
     
146. BHAT KRS, Covas Moschovas M, Sandri M, Dell'Oglio P, et al
     A Predictive Preoperative and Postoperative Nomogram for Postoperative Potency Recovery after Robot-Assisted Radical Prostatectomy.
     J Urol. 2021;206:942-951.
     PubMed     Abstract available
     
     
     September 2021
147. CHIERIGO F, Wenzel M, Wurnschimmel C, Flammia RS, et al
     Survival after Radical Prostatectomy vs. Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer.
     J Urol. 2021 Sep 24:101097JU0000000000002250. doi: 10.1097/JU.0000000000002250.
     PubMed     Abstract available
     
     
     
148. LEAPMAN MS, Stone K, Wadia R, Park LS, et al
     Prostate Cancer Screening and Incidence Among Aging Persons Living with HIV.
     J Urol. 2021 Sep 24:101097JU0000000000002249. doi: 10.1097/JU.0000000000002249.
     PubMed     Abstract available
     
     
     
149. MARTINI A, Soeterik TFW, Haverdings H, Rahota RG, et al
     An Algorithm to Personalize Nerve Sparing in Men with Unilateral High-Risk Prostate Cancer.
     J Urol. 2021 Sep 22:101097JU0000000000002205. doi: 10.1097/JU.0000000000002205.
     PubMed     Abstract available
     
     
     
150. XUE AL, Kalapara AA, Ballok ZE, Levy SM, et al
     (68)Ga-PSMA PET SUVmax as a Predictor of Gleason Pattern 4 and Pathologic Upgrading in Intermediate Risk Prostate Cancer.
     J Urol. 2021 Sep 21:101097JU0000000000002254. doi: 10.1097/JU.0000000000002254.
     PubMed     Abstract available
     
     
     
151. KRAMER JJ, Gu L, Moreira D, Andriole G, et al
     Statin Use and Lower Urinary Tract Symptoms (LUTS) Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial.
     J Urol. 2021 Sep 21:101097JU0000000000002199. doi: 10.1097/JU.0000000000002199.
     PubMed     Abstract available
     
     
     
152. MONTORSI F, Leni R, Briganti A, Gandaglia G, et al
     Association of Negative Followup Biopsy and Reclassification during Active Surveillance of Prostate Cancer: A Systematic Review and Meta-Analysis. Letter.
     J Urol. 2021 Sep 16:101097JU0000000000002245. doi: 10.1097/JU.0000000000002245.
     PubMed    
     
     
     
153. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2021 Sep 9:101097JU0000000000002226. doi: 10.1097/JU.0000000000002226.
     PubMed    
     
     
     
154. GREENBERG SA, Washington SL 3rd, Lonergan PE, Cowan JE, et al
     Residual Benign Prostate Glandular Tissue after Radical Prostatectomy is Not Associated with the Development of Detectable Postoperative Serum Prostate Specific Antigen.
     J Urol. 2021;206:706-714.
     PubMed     Abstract available
     
     
     
155. EHDAIE B, Jibara G, Sjoberg DD, Laudone V, et al
     The Duration of Antibiotics Prophylaxis at the Time of Catheter Removal after Radical Prostatectomy: Clinically Integrated, Cluster, Randomized Trial.
     J Urol. 2021;206:662-668.
     PubMed     Abstract available
     
     
     
156. HINES L, Zhu D, DeMasi M, Babar M, et al
     A Comparison of Image-Guided Targeted Prostate Biopsy Outcomes by PI-RADS(R) Score and Ethnicity in a Diverse, Multiethnic Population.
     J Urol. 2021;206:586-594.
     PubMed     Abstract available
     
     
     
157. SOERENSEN SJC, Fan RE, Seetharaman A, Chen L, et al
     Deep Learning Improves Speed and Accuracy of Prostate Gland Segmentations on Magnetic Resonance Imaging for Targeted Biopsy.
     J Urol. 2021;206:604-612.
     PubMed     Abstract available
     
     
     August 2021
158. KIM M, Wu S, Lin SX, Crotty RK, et al
     Transperineal Multiparametric Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy Combined with Standard Template Improves Prostate Cancer Detection.
     J Urol. 2021 Aug 25:101097JU0000000000002168. doi: 10.1097/JU.0000000000002168.
     PubMed     Abstract available
     
     
     
159. TIMILSHINA N, Komisarenko M, Martin LJ, Cheung DC, et al
     Factors Associated With Discontinuation of Active Surveillance among Men With Low-Risk Prostate Cancer: A Population-Based Study.
     J Urol. 2021 Aug 20:101097JU0000000000001903. doi: 10.1097/JU.0000000000001903.
     PubMed     Abstract available
     
     
     
160. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2021 Aug 18:101097JU0000000000002174. doi: 10.1097/JU.0000000000002174.
     PubMed    
     
     
     
161. COOLEY LF, Emeka AA, Meyers TJ, Cooper PR, et al
     Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort.
     J Urol. 2021 Aug 16:101097JU0000000000001937. doi: 10.1097/JU.0000000000001937.
     PubMed     Abstract available
     
     
     
162. KHEDIME S, Gelet A, Rouviere O, Lafon C, et al
     Salvage High-Intensity Focused Ultrasound for Local Recurrence in the Prostatic Bed after Prostatectomy and Adjuvant or Salvage Radiotherapy: Preliminary Results.
     J Urol. 2021;206:325-337.
     PubMed     Abstract available
     
     
     
163. TAFURI A, Iwata A, Shakir A, Iwata T, et al
     Systematic Biopsy of the Prostate can Be Omitted in Men with PI-RADS 5 and Prostate Specific Antigen Density Greater than 15.
     J Urol. 2021;206:289-297.
     PubMed     Abstract available
     
     
     
164. KUMAR RM, Fergusson DA, Lavallee LT, Cagiannos I, et al
     Performance Feedback May Not Improve Radical Prostatectomy Outcomes: The Surgical Report Card (SuRep) Study.
     J Urol. 2021;206:346-353.
     PubMed     Abstract available
     
     
     July 2021
165. RYAN CJ, Ke X, Lafeuille MH, Romdhani H, et al
     Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States.
     J Urol. 2021 Jul 23:101097JU0000000000002121. doi: 10.1097/JU.0000000000002121.
     PubMed     Abstract available
     
     
     
166. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2021 Jul 20:101097JU0000000000002132. doi: 10.1097/JU.0000000000002132.
     PubMed    
     
     
     
167. FREEDLAND SJ, Howard LE, Ngo A, Ramirez-Torres A, et al
     Low Carbohydrate Diets and Estimated Cardiovascular and Metabolic Syndrome Risk in Prostate Cancer.
     J Urol. 2021 Jul 14:101097JU0000000000002112. doi: 10.1097/JU.0000000000002112.
     PubMed     Abstract available
     
     
     
168. ROMPRE-BRODEUR A, Marcq G, Tholomier C, Fugaru I, et al
     Role of Systematic Control Biopsies Following Partial Gland Ablation with High-Intensity Focused Ultrasound for Clinically Significant Prostate Cancer.
     J Urol. 2021 Jul 12:101097JU0000000000001934. doi: 10.1097/JU.0000000000001934.
     PubMed     Abstract available
     
     
     
169. PURYSKO AS, Bullen J, Valdez R, Auschof E, et al
     Influence of 5-Alpha Reductase Inhibitors on Prostate Cancer Detection With MRI: A Matched Cohort Study.
     J Urol. 2021 Jul 6:101097JU0000000000001932. doi: 10.1097/JU.0000000000001932.
     PubMed     Abstract available
     
     
     June 2021
170. TREMBLAY S, Summers-Trasiewicz L, Pouliot F, Crook JM, et al
     Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer.
     J Urol. 2021 Jun 29:101097JU0000000000001946. doi: 10.1097/JU.0000000000001946.
     PubMed     Abstract available
     
     
     
171. OAKE JD, Harasemiw O, Tangri N, Ferguson TW, et al
     The Association Between Income Status and Treatment Selection for Prostate Cancer in a Universal Healthcare System: A Population-Based Analysis.
     J Urol. 2021 Jun 28:101097JU0000000000001942. doi: 10.1097/JU.0000000000001942.
     PubMed     Abstract available
     
     
     
172. WILLIAMS C, Khondakar NR, Daneshvar MA, O'Connor LP, et al
     The Risk of Prostate Cancer Progression in Active Surveillance Patients With Bilateral Disease Detected by Combined MRI-Fusion and Systematic Biopsy.
     J Urol. 2021 Jun 28:101097JU0000000000001941. doi: 10.1097/JU.0000000000001941.
     PubMed     Abstract available
     
     
     
173. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2021 Jun 21:101097JU0000000000001921. doi: 10.1097/JU.0000000000001921.
     PubMed    
     
     
     
174. INABA H, Kimura T, Onuma H, Kido M, et al
     Tumor Location and Pathological Features of Latent and Incidental Prostate Cancer in Contemporary Japanese Men. Reply.
     J Urol. 2021;205:1841-1842.
     PubMed    
     
     
     
175. VAN KALMTHOUT L, Braat A, de Keizer B, Lam M, et al
     Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer. Reply.
     J Urol. 2021;205:1839-1840.
     PubMed    
     
     
     
176. AMIEL T, Wurnschimmel C, Heck M, Horn T, et al
     Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Obs
     J Urol. 2021;205:1663-1670.
     PubMed     Abstract available
     
     
     
177. DALY WC, Linscott JA, Han PKJ, Hayn MH, et al
     National Recommendations against Prostate Specific Antigen Screening versus Statewide Medicaid Expansion Initiatives: A Battle of the Titans.
     J Urol. 2021;205:1641-1647.
     PubMed     Abstract available
     
     
     
178. PATEL HD, Schwen ZR, Campbell JD, Gorin MA, et al
     Effect of Erythropoietin on Erectile Function after Radical Prostatectomy: The ERECT Randomized Clinical Trial.
     J Urol. 2021;205:1681-1688.
     PubMed     Abstract available
     
     
     May 2021
179. AGARWAL N, McQuarrie K, Bjartell A, Chowdhury S, et al
     Apalutamide Plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study.
     J Urol. 2021 May 27:101097JU0000000000001841. doi: 10.1097/JU.0000000000001841.
     PubMed     Abstract available
     
     
     
180. LIFSHITZ K, Ber Y, Shenhar C, Nillson J, et al
     Cardiovascular Proteomics: A Post-hoc Analysis from a Phase II Randomized Clinical Trial Comparing GnRH Antagonist Vs GnRH Agonist Among Men with Advanced Prostate Cancer.
     J Urol. 2021 May 25:101097JU0000000000001879. doi: 10.1097/JU.0000000000001879.
     PubMed     Abstract available
     
     
     
181. CHEUNG DC, Alibhai SMH, Martin LJ, Komisarenko M, et al
     Real World Practice Patterns and Predictors of Continuous versus Intermittent ADT Use for Prostate Cancer in Older Men.
     J Urol. 2021 May 25:101097JU0000000000001876. doi: 10.1097/JU.0000000000001876.
     PubMed     Abstract available
     
     
     
182. MARSHALL CH, Chen Y, Kuo C, Cullen J, et al
     Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies.
     J Urol. 2021 May 18:101097JU0000000000001797. doi: 10.1097/JU.0000000000001797.
     PubMed     Abstract available
     
     
     
183. MACDONALD S, Matos A, Wambier C
     Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection With SARS-CoV-2. Letter.
     J Urol. 2021 May 17:101097JU0000000000001883. doi: 10.1097/JU.0000000000001883.
     PubMed    
     
     
     
184. KLEIN EA
     Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection with SARS-CoV-2. Reply.
     J Urol. 2021 May 17:101097JU0000000000001884. doi: 10.1097/JU.0000000000001884.
     PubMed    
     
     
     
185. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2021 May 17:101097JU0000000000001865. doi: 10.1097/JU.0000000000001865.
     PubMed    
     
     
     
186. SHAH N, Ioffe V
     Selecting Patients with Favorable Risk, Grade Group 2 Prostate Cancer for Active Surveillance-Does Magnetic Resonance Imaging Have a Role? Letter.
     J Urol. 2021 May 13:101097JU0000000000001880. doi: 10.1097/JU.0000000000001880.
     PubMed    
     
     
     
187. MENG X, Chao B, Chen F, Huang R, et al
     Followup of Men with PI-RADS(TM) 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy. Reply.
     J Urol. 2021;205:1528-1529.
     PubMed    
     
     
     
188. STAVRINIDES V, Giganti F, Allen C, Kirkham A, et al
     Followup of Men with PI-RADS(TM) 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy. Letter.J Urol 2021; 205: 748.
     J Urol. 2021;205:1526-1528.
     PubMed    
     
     
     
189. PUNNEN S, Stoyanova R, Kwon D, Reis IM, et al
     Heterogeneity in Genomic Risk Assessment from Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of Magnetic Resonance Imaging Targeted Biopsy.
     J Urol. 2021;205:1344-1351.
     PubMed     Abstract available
     
     
     
190. MATULEWICZ RS, Basak R, Zambrano I, Dearing BA, et al
     Patterns of Current Cigarette Smoking, Quit Attempts and Cessation Counseling among Survivors of Smoking-Related and Nonsmoking-Related Urological Malignancies: A Nationally Representative Cross-Sectional Analysis.
     J Urol. 2021;205:1444-1451.
     PubMed     Abstract available
     
     
     April 2021
191. RAMAN AG, Sarma KV, Raman SS, Priester AM, et al
     Optimizing Spatial Biopsy Sampling for the Detection of Prostate Cancer.
     J Urol. 2021 Apr 28:101097JU0000000000001832. doi: 10.1097/JU.0000000000001832.
     PubMed     Abstract available
     
     
     
192. CHIN JL, Lavi A, Metcalfe MJ, Siddiqui K, et al
     Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer Following Radiation Therapy: A Combined Analysis of Two Centers.
     J Urol. 2021 Apr 28:101097JU0000000000001831. doi: 10.1097/JU.0000000000001831.
     PubMed     Abstract available
     
     
     
193. LEYH-BANNURAH SR, Liakos N, Oelke M, Wagner C, et al
     Peri- and Postoperative Outcomes of Robot-Assisted Radical Prostatectomy in Prostate Cancer Patients with Prior Transurethral Subvesical Deobstruction: Results of a High-Volume Center.
     J Urol. 2021 Apr 27:101097JU0000000000001776. doi: 10.1097/JU.0000000000001776.
     PubMed     Abstract available
     
     
     
194. FAN L, Fei X, Zhu Y, Chi C, et al
     Distinct Response to Platinum-Based Chemotherapy Among Patients With Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
     J Urol. 2021 Apr 27:101097JU0000000000001819. doi: 10.1097/JU.0000000000001819.
     PubMed     Abstract available
     
     
     
195. RAJWA P, Mori K, Huebner NA, Martin DT, et al
     The Prognostic Association of Prostate MRI PI-RADS v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.
     J Urol. 2021 Apr 27:101097JU0000000000001821. doi: 10.1097/JU.0000000000001821.
     PubMed     Abstract available
     
     
     
196. STABILE A, Sanchez-Salas R, Tourinho-Barbosa R, Macek P, et al
     Association Between Lesion Location and Oncological Outcomes after Focal Therapy for Localized Prostate Cancer Using Either High Intensity Focused Ultrasound or Cryotherapy.
     J Urol. 2021 Apr 23:101097JU0000000000001787. doi: 10.1097/JU.0000000000001787.
     PubMed     Abstract available
     
     
     
197. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2021 Apr 21:101097JU0000000000001814. doi: 10.1097/JU.0000000000001814.
     PubMed    
     
     
     
198. ZHANG KW, Reimers MA, Calaway AC, Fradley MG, et al
     Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS).
     J Urol. 2021 Apr 19:101097JU0000000000001785. doi: 10.1097/JU.0000000000001785.
     PubMed     Abstract available
     
     
     
199. LIN PH, Howard L, Freedland SJ
     Impact of Low Carbohydrate Diet on Self-Report Fatigue and Weakness in Prostate Cancer Patients.
     J Urol. 2021 Apr 5:101097JU0000000000001780. doi: 10.1097/JU.0000000000001780.
     PubMed    
     
     
     
200. HALABI S, Jiang S, Terasawa E, Garcia-Horton V, et al
     Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
     J Urol. 2021 Apr 5:101097JU0000000000001767. doi: 10.1097/JU.0000000000001767.
     PubMed     Abstract available
     
     
     
201. MATSUMOTO K, Omura M, Takeda T, Kosaka T, et al
     Grading of Multifocal Prostate Cancer Cases in which the Largest Volume and the Highest Grade do Not Coincide within One Lesion.
     J Urol. 2021 Apr 5:101097JU0000000000001765. doi: 10.1097/JU.0000000000001765.
     PubMed     Abstract available
     
     
     March 2021
202. BABAJIDE R, Carbunaru S, Nettey OS, Watson KS, et al
     Performance of Prostate Health Index in Biopsy Naive Black Men.
     J Urol. 2021;205:718-724.
     PubMed     Abstract available
     
     
     
203. UMARI P, Eden C, Cahill D, Rizzo M, et al
     Retzius-Sparing versus Standard Robot-Assisted Radical Prostatectomy: A Comparative Prospective Study of Nearly 500 Patients.
     J Urol. 2021;205:780-790.
     PubMed     Abstract available
     
     
     
204. TOSOIAN JJ, Trock BJ, Morgan TM, Salami SS, et al
     Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach.
     J Urol. 2021;205:732-739.
     PubMed     Abstract available
     
     
     
205. MENG X, Chao B, Chen F, Huang R, et al
     Followup of Men with PI-RADS 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy.
     J Urol. 2021;205:748-754.
     PubMed     Abstract available
     
     
     
206. FEUER Z, Meng X, Rosenkrantz AB, Kasivisvanathan V, et al
     Application of the PRECISION Trial Biopsy Strategy to a Contemporary Magnetic Resonance Imaging-Targeted Biopsy Cohort-How Many Clinically Significant Prostate Cancers are Missed?
     J Urol. 2021;205:740-747.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: